Advanced Models and Novel I/O Technologies for Preclinical PDAC Research

July 9, 2019

This White Paper presents orthotopic tumor homografts as a clinically-relevant pancreatic cancer preclinical model, which more accurately replicates the TME in vivo. These immunocompetent models allow advanced assessment of novel agents targeting the disease, including immunotherapies.

Spotlight

Greenfield Biotech

As a part of this we have started Greenfield Biotech in the green and the capital city of Garvi Gujarat in the year 2012 with very strong Biotechnology background and with initial production capicity of 1.5 million plants per anum.

OTHER WHITEPAPERS
news image

Could DNA be the next big thing in data storage?

whitePaper | August 19, 2021

DNA storage technology is advancing rapidly. Atos is closely monitoring the development of this technology in the hope that future developments will make it a scalable, cost effective and crucially a decarbonized alternative to today’s carbon intensive technologies.

Read More
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More
news image

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More
news image

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Read More
news image

Automated Extraction of High Molecular Weight DNA

whitePaper | November 14, 2019

SmartExtraction significantly simplifies the entire automated workflow of DNA extraction, setting new standards with regard to efficiency, yield and quality of the DNA.

Read More
news image

New Diagnostic Approaches for Undiagnosed Rare Genetic Diseases

whitePaper | April 16, 2020

Accurate diagnosis is the cornerstone of medicine; it is essential for informed care and promoting patient and family well-being. However, families with a rare genetic disease (RGD) often spend more than five years on a diagnostic odyssey of specialist visits and invasive testing that is lengthy, costly, and often futile, as 50% of patients do not receive a molecular diagnosis.

Read More

Spotlight

Greenfield Biotech

As a part of this we have started Greenfield Biotech in the green and the capital city of Garvi Gujarat in the year 2012 with very strong Biotechnology background and with initial production capicity of 1.5 million plants per anum.

Events